PegBio Co

PegBio Co Interest Expense

The Interest Expense of PegBio Co (2565.HK) as of Oct 15, 2026 is 4.32 M CNY. In the previous year, Interest Expense was 9.88 M CNY — a change of -56.33% (lower).

Interest Expense

4.32 MCNY

YoY

-56.33%

Last updated:

Interest Expense of PegBio Co is 2024 4.32 M CNY. Interest Expense of PegBio Co was 2023 9.88 M CNY. It decreases by -56.33% lower compared to the previous year.

The PegBio Co Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2023
9.88 M CNY
Jan 1, 2024
4.32 M CNY
The PegBio Co Interest Expense history
YEARInterest ExpenseYoY
4.32 MCNY-56.33%
9.88 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co Stock analysis

What does PegBio Co do? PegBio Co Ltd is a biotechnology company based in Hangzhou, China, operating within the healthcare sector. The company focuses on the research, development, and production of innovative drugs targeting chronic disease treatment. PegBio is set to go public with an IPO scheduled for May 27, 2025, under the ticker 2565.HK. The company's website is https://www.pegbio.com/. PegBio's primary product, PB-119, is described as a self-developed, near-commercialized long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. GLP-1 is a peptide hormone involved in blood sugar regulation. The company also lists several product candidates, including PB-718, PB-1902, PB-722, PB-2301, and PB-2309. These products are intended for the treatment of various chronic and metabolic conditions, such as type 2 diabetes mellitus (T2DM), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia. Congenital hyperinsulinemia is a rare endocrine disorder characterized by persistent low blood sugar levels. PegBio's focus areas include metabolic diseases and chronic conditions requiring ongoing therapeutic management. The company's operational headquarters is located in Hangzhou, Zhejiang Province, China. As a biotechnology firm, PegBio operates within the broader healthcare industry, emphasizing drug development for unmet medical needs in chronic disease management. PegBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PegBio Co stock

Interest Expense of PegBio Co is 4.32 M CNY in 2024.

Interest Expense of PegBio Co changed from 9.88 M CNY to 4.32 M CNY, representing a -56.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense PegBio Co since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's PegBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — PegBio Co

All Key Metrics — PegBio Co